Developments FDA clears Solid’s IND application for SGT-212 in FA Solid Biosciences (NASDAQ:SLBD) announced that the FDA has cleared its IND application for SGT-212, a first-in-industry dual-route of administration gene therapy designed to treat the neurologic and cardiac... January 8, 2025